[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

Ida Wong-SefidanDepartment of Haematology/Oncology, Moores Cancer Center, University of California, San Diego, CA, USA; Correspondence[email protected]

Michelle ByrtekStatistics, Genentech Inc., South San Francisco, CA, USA;

Xiaolei ZhouBiostatistics, RTI Health Solutions, Research Triangle Park, NC, USA;

Jonathan W. FriedbergSchool of Medicine and Dentistry, University of Rochester, Rochester, NY, USA;

Christopher R. FlowersWinship Cancer Institute, Emory University, Atlanta, GA, USA;

Andrew D. ZelenetzDepartment of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

Keith L. DawsonMedical Affairs, Genentech Inc., South San Francisco, CA, USA

Erin ReidDepartment of Haematology/Oncology, Moores Cancer Center, University of California, San Diego, CA, USA;

show all

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date